rhinovirus
rv
caus
common
cold
associ
exacerb
chronic
inflammatori
respiratori
diseas
especi
asthma
chronic
obstruct
pulmonari
diseas
copd
assess
antivir
drug
anaferon
children
ac
ergoferon
contain
ac
one
activ
pharmaceut
ingredi
vitro
vivo
experiment
model
order
evalu
antirhinovir
immunomodulatori
potenti
hela
cell
pretreat
ac
level
interferonstimul
gene
isg
oligoadenyl
synthetas
viral
replic
analyz
mous
model
rvinduc
exacerb
allerg
airway
inflamm
administ
ergoferon
analyz
effect
type
ifnb
type
ii
ifng
type
iii
ifnl
ifn
induct
cell
count
bronchoalveolar
lavag
bal
cytokin
interleukin
il
chemokin
level
shown
ac
increas
product
significantli
decreas
viral
replic
vitro
increas
ifn
express
togeth
reduc
neutrophilslymphocyt
recruit
correl
declin
demonstr
ergoferon
vivo
howev
effect
examin
chemokin
conclud
ac
ergoferon
possess
effect
rv
infect
may
potenti
novel
therapi
rvinduc
exacerb
asthma
asthma
preval
respiratori
diseas
affect
adult
children
european
societi
asher
et
al
worldwid
time
trend
preval
symptom
asthma
allerg
rhinoconjunct
eczema
childhood
isaac
phase
one
three
repeat
multicountri
crosssect
survey
asthma
occurr
increas
recent
decad
trend
like
continu
major
morbid
health
care
cost
relat
asthma
result
acut
exacerb
weiss
sullivan
gener
trigger
viral
infect
lower
respiratori
tract
respiratori
syncyti
virus
rsv
human
metapneumovirus
hmpv
coronavirus
influenza
virus
common
human
rhinoviru
rv
papadopoulo
et
al
wood
et
al
rv
account
around
viru
induc
asthma
exacerb
current
vaccin
antivir
therapi
exist
rvinduc
asthma
exacerb
therefor
clear
unmet
medic
need
inhal
steroid
mainstay
asthma
treatment
johnston
et
al
howev
adult
reduc
exacerb
frequenc
pauwel
et
al
combin
longact
b
agonist
therapi
e
around
pauwel
et
al
situat
even
wors
children
preschool
school
age
children
prophylact
inhal
steroid
ineffect
reduct
exacerb
frequenc
durat
sever
doull
et
al
oommen
et
al
great
major
asthma
exacerb
continu
occur
despit
use
current
therapi
thu
indic
limit
efficaci
therefor
necessit
develop
novel
treatment
paper
present
result
protect
activ
antivir
drug
ac
ergoferon
antivir
efficaci
alreadi
report
tarasov
et
al
kudin
et
al
sergeev
et
al
shishkina
et
al
erman
et
al
rafalski
et
al
shilovski
ip
et
al
vitro
vivo
model
rv
infect
ergoferon
ac
diluent
control
blind
suppli
code
ooo
npf
materia
medica
hold
russia
moscow
readytous
aqueou
solut
activ
pharmaceut
ingredi
api
drug
manufactur
base
novel
patent
biotechnolog
platform
us
patent
use
follow
affin
purifi
rabbit
polyclon
antibodi
ab
start
substanc
ab
interferon
ifn
g
ab
ab
histamin
ergoferon
ab
ifng
ac
formul
therefor
technologicallytr
form
ab
ifng
api
ac
ergoferon
substanc
manufactur
accord
current
eu
requir
gmp
start
materi
eu
direct
amend
direct
angel
biotechnolog
hold
plc
uk
edinburgh
ab
ifng
ab
biotechnolog
edinburgh
uk
ab
receptor
ab
histamin
diluent
name
purifi
water
use
test
drug
manufactur
serv
control
examin
procedur
commerci
avail
supplier
provid
ifnb
r
system
steril
solut
iuml
use
vitro
experi
refer
product
ifng
aqueou
solut
ooo
npf
materia
medica
hold
use
induc
cell
cultur
experi
antihuicam
purchas
r
system
uk
concentr
mgml
use
vivo
research
human
rhinoviru
serotyp
human
rhinoviru
serotyp
origin
obtain
atcc
catno
catno
titrat
propag
hela
cell
ascertain
tissu
cultur
infect
dose
tcid
cell
lysat
kept
c
approxim
tcid
ml
vitro
tcid
ml
vivo
experi
respect
virus
neg
mycoplasma
infect
ohio
hela
cell
atcc
catno
cultur
steril
condit
accord
standard
protocol
see
supplementari
materi
util
vitro
studi
hela
cell
atcc
catno
crl
use
viral
propag
vivo
experi
procedur
cell
cultur
virus
carri
class
ii
facil
equip
high
effici
filter
accord
highest
environ
protect
eec
standard
week
old
human
transgen
balbc
mice
gener
hous
describ
elsewher
bartlett
et
al
hous
individu
ventil
cage
specif
pathogen
free
anim
facil
free
access
food
water
mice
acclimat
day
treatment
anim
screen
huicam
transgen
express
pcr
huicam
mice
dob
identifi
select
present
studi
anim
procedur
complet
accord
uk
home
offic
guidelin
ethic
approv
process
uk
project
licens
ppl
valid
order
evalu
antivir
activ
ac
vitro
ohio
hela
cell
inocul
follow
infect
cell
cultur
either
presenc
ac
diluent
pure
dmem
medium
neg
control
see
supplementari
materi
ac
refer
product
ifnb
differ
dose
uiml
diluent
ad
daili
durat
studi
cell
supernat
experiment
group
harvest
h
addit
sampl
medium
distribut
plate
well
result
present
pool
experi
perform
duplic
data
present
percentag
mediumtr
cell
quantit
pcr
carri
use
specif
primer
probe
gene
see
supplementari
materi
express
antivir
isg
measur
hela
cell
treat
ifng
alon
combin
ac
follow
cell
stimul
ifng
dose
rang
ui
ml
detail
see
supplementari
materi
cell
expos
ac
mixtur
dmem
mediumifng
h
cell
lysat
harvest
analyz
isg
presenc
procedur
perform
independ
experi
duplic
result
present
rel
mediumtr
cell
transgen
huicam
mice
use
experi
describ
bartlett
et
al
gener
inform
breed
procedur
detail
supplementari
materi
four
mice
group
remain
noninfect
consid
baselin
h
treatment
group
n
mice
receiv
ergoferon
twice
daili
day
day
inocul
viru
neg
control
group
n
given
diluent
compar
dose
regimen
ergoferon
group
group
receiv
refer
product
n
dose
antihuicam
intranas
h
prior
inocul
traub
et
al
base
scheme
experi
present
fig
total
rna
extract
upper
left
lobe
mous
lung
place
rna
later
qiagen
prior
rna
extract
cdna
synthesi
conduct
qpcr
experi
specif
primer
probe
gene
use
describ
manufactur
procedur
ifn
gene
express
measur
e
h
lung
mice
cannul
via
trachea
lavag
ml
bal
buffer
rpmi
mm
edta
total
bal
separ
cell
supernat
fraction
cell
count
perform
trypan
blue
sigmaaldrich
uk
use
hemocytomet
chang
bal
level
examin
immedi
h
h
day
viral
inocul
cytokin
chemokin
ifnginduc
protein
analysi
determin
cellfre
bal
fluid
elisa
rnd
system
usa
accord
manufactur
instruct
h
post
infect
pi
vitro
vivo
data
distribut
normal
present
mean
standard
error
mean
sem
depend
experi
result
present
normal
mediumtr
cell
comparison
differ
group
analyz
anova
r
softwar
r
foundat
statist
comput
vienna
austria
posthoc
dunnett
test
vivo
experi
kruskalw
test
posthoc
nemenyi
analysi
carri
pvalu
consid
signific
ohio
hela
cell
model
rv
infect
assess
effect
ac
viral
rna
vrna
abund
titrat
moi
use
vitro
shown
refer
product
ifnb
could
inhibit
viral
replic
dosedepend
manner
reduct
statist
signific
p
ifnb
uiml
dose
fig
ac
dilut
test
alongsid
ifnb
work
dilut
defin
base
previous
conduct
cytotox
studi
h
p
vrna
significantli
reduc
ac
versu
dmem
medium
alon
fig
p
ac
reduct
vrna
observ
dose
depend
manner
dilut
show
greater
reduct
dilut
decreas
order
assess
influenc
ac
treatment
isg
cell
supernat
harvest
titrat
hela
cell
calcul
tcid
n
per
ifnb
group
n
per
medium
group
p
versu
medium
treat
cell
result
analyz
oneway
anova
posthoc
dunnett
test
express
rel
mediumtr
cell
moi
test
sampl
diluent
medium
ad
h
prior
infect
induc
mrna
level
rv
replic
result
measur
h
pi
realtim
qpcr
n
duplic
p
versu
medium
treat
cell
data
analyz
oneway
anova
posthoc
dunnett
test
present
rel
mediumtr
cell
express
ac
dilut
ifng
rang
dose
uiml
ad
hela
cell
gene
analys
import
antivir
gene
involv
innat
immun
respons
isg
capabl
regul
rnabas
viru
replic
expect
bare
detect
absenc
ifng
strongli
stimul
iuml
dose
ifng
show
signific
level
isg
induct
fig
gene
level
increas
dosedepend
manner
exceed
control
cell
stimul
ifng
iuml
dose
least
fig
view
dose
rang
iuml
consid
ideal
assess
effect
ac
contrast
diluent
case
level
decreas
ac
promot
effect
trend
particularli
pronounc
dose
iuml
ifng
howev
observ
increas
statist
signific
fig
use
mous
model
major
group
exacerb
allerg
airway
inflamm
test
efficaci
oral
treatment
ergoferon
induct
antivir
environ
well
reduct
airway
inflamm
ergoferon
significantli
increas
ifnb
p
gene
express
h
infect
comparison
refer
fig
amount
ifng
gradual
elev
studi
experi
result
insignific
p
augment
trend
ifnl
gene
product
observ
presenc
ergoferon
h
pi
group
quantiti
gene
almost
initi
level
differ
group
fig
next
sought
determin
effect
ergoferon
treatment
accumul
inflammatori
cell
within
bal
follow
rv
fig
effect
dose
rang
ifng
iuml
number
copi
hela
cell
seed
treat
ifng
iuml
dmem
medium
h
cell
lysat
harvest
number
copi
measur
qpcr
normal
rrna
express
normal
copi
number
per
ml
cdna
n
p
p
compar
medium
treat
cell
result
analyz
oneway
anova
posthoc
dunnett
test
present
rel
mediumtr
cell
effect
ac
dilut
combin
ifng
dose
rang
hela
cell
seed
treat
mixtur
ifng
iuml
ac
diluent
pure
dmem
medium
h
ifng
stimul
mrna
extract
result
normal
rrna
express
normal
copi
number
per
ml
cdna
n
data
present
rel
mediumtr
cell
infect
ergoferon
show
signific
efficaci
alter
cell
traffick
number
lymphocyt
decreas
p
h
pi
compar
refer
product
day
p
versu
diluent
fig
differ
refer
antihuicam
ab
diluent
day
pi
p
also
shown
number
neutrophil
mice
treat
ergoferon
significantli
reduc
h
p
h
pi
p
refer
group
neutrophil
count
presenc
refer
higher
diluenttr
mice
differ
statist
signific
day
neutrophil
return
baselin
valu
howev
cell
number
diluent
treat
mice
remain
lower
ergoferon
p
refer
group
statist
signific
chang
macrophag
eosinophil
count
examin
group
data
shown
level
cytokin
chemokin
within
airway
determin
via
elisa
bal
result
experi
bal
cytokin
level
indic
ergoferon
increas
level
h
pi
rel
refer
product
p
sharp
signific
declin
compar
diluent
h
p
versu
diluent
refer
group
higher
level
bal
cytokin
compar
ergoferon
p
diluent
h
pi
dynam
express
similar
statist
signific
reduct
group
observ
h
pi
p
ergoferon
vs
diluent
chemokin
level
bal
analyz
term
express
result
similar
analyt
data
statist
insignific
whole
timelin
group
data
obtain
refer
group
correspond
ergoferon
treat
mice
fig
vital
need
exist
new
treatment
option
rv
infect
song
hyden
weinberg
zhu
et
al
well
known
rv
enter
host
cell
lead
direct
rapid
activ
kinas
downstream
activ
protein
kinas
b
akt
nuclear
factor
kappa
b
nfkb
christman
et
al
infect
result
ifn
respons
defici
asthma
contoli
et
al
gener
proinflammatori
cytokin
neutrophil
lymphocyt
infiltr
therefor
one
potenti
approach
therapi
rv
infect
augment
host
ifn
respons
induc
product
antivir
isg
express
dhariw
et
al
aim
assess
express
antivir
gene
mrna
viral
replic
bal
cell
cytokin
vitro
vivo
model
vitro
experi
carri
use
hela
cell
standard
model
analyz
effect
intervent
rv
cope
hofer
et
shafren
et
al
import
agent
involv
one
establish
antivir
system
e
coupl
oligoadenyl
synthetas
oa
rnase
l
pathway
liang
et
al
solina
et
al
shulman
revel
castelli
et
al
chosen
among
list
ifng
induc
gene
demonstr
isg
respons
presenc
ac
upward
dynam
express
whole
ifng
dose
rang
exceed
diluent
level
least
twofold
moreov
enhanc
product
compar
mediumtr
cell
detect
uiml
ifng
rv
replic
data
correspond
isg
mrna
research
inde
vrna
abund
statist
lower
dose
ac
versu
medium
treat
cell
result
compar
ifnb
uiml
behavior
also
true
dose
ac
howev
statist
signific
analyz
group
observ
effect
could
potenti
explain
low
sampl
concentr
suffici
inhibit
rv
replic
equal
respect
ifnb
uiml
still
enough
stimul
product
previous
shown
key
mechan
ac
action
abil
improv
ligandreceptor
interact
ifng
ifng
receptor
via
conform
chang
ifng
molecul
zhavbert
et
al
epstein
chang
lead
function
activ
regul
product
endogen
ifn
henc
affect
antivir
defens
consequ
induct
demonstr
experi
correspond
ac
mechan
action
coincid
literatur
increas
product
isg
connect
augment
ifn
induct
like
ac
augment
gene
also
import
antivir
respons
fact
character
isg
der
et
al
also
induc
ifng
unfortun
beyond
scope
present
studi
measur
isg
stress
respect
necess
conduct
addit
studi
address
mechan
observ
antirv
effect
ac
monocompon
drug
contain
api
technologicallytr
ab
ifng
use
initi
experi
see
whether
could
demonstr
antivir
activ
rv
vitro
innat
respons
induc
observ
encourag
result
opt
use
eroferon
addit
technologicallytr
ab
ifng
also
contain
ab
ab
histamin
order
show
whether
could
addit
observ
immunomodulatori
antiinflammatori
effect
complex
vivo
environ
innat
acquir
immun
respons
well
inflammatori
respons
studi
previous
shown
ergoferon
could
influenc
variou
element
host
antivir
protect
system
induc
endogen
ifn
emelyanova
et
al
histamin
receptor
zhavbert
et
al
gener
express
macrophag
dendrit
cell
tcell
studi
report
treatment
ergoferon
improv
virusinduc
exacerb
ovalbumininduc
allerg
airway
inflamm
ergoferon
result
increas
ifnmrna
express
mainli
ifnb
greatest
degre
detect
h
pi
ifn
gene
express
level
assess
rna
extract
upper
left
lobe
mous
lung
therefor
say
cell
type
induc
addit
decreas
lymphocyt
neutrophil
airway
inflamm
also
observ
ergoferon
exposur
known
cytokin
play
import
role
pathophysiolog
allerg
diseas
asthma
could
use
potenti
therapeut
target
futur
manag
beal
et
al
previous
shown
model
rvinduc
exacerb
allerg
airway
inflamm
day
pi
larg
number
lymphocyt
lung
airway
exacerb
mice
characterist
therefor
like
cell
recruit
suppress
ergoferon
given
magnitud
reduct
total
lymphocyt
report
herein
day
suppress
respons
support
suppress
steink
borish
observ
ergoferon
treat
mice
compar
diluent
group
h
pi
fig
b
neutrophil
also
import
compon
rvinduc
inflamm
may
contribut
upper
lower
airway
respons
process
rv
infect
turner
jarjour
et
al
tempor
progress
respons
rv
eventu
increas
airway
neutrophil
inflamm
could
contribut
exacerb
asthma
thu
neutrophil
reduct
ergoferontr
group
observ
h
h
pi
could
connect
reduct
inflammatori
process
surprisingli
us
bal
cytokin
profil
caus
sudden
increas
product
h
pi
subsequ
signific
reduct
h
compar
diluent
treat
group
biolog
mean
observ
increas
h
point
clear
differenti
whether
increas
proinflammatori
cytokin
due
ifn
activ
start
h
p
still
result
increas
lymphocyt
neutrophil
inflamm
lung
sum
decreas
cell
attract
cytokin
express
notic
ergoferon
h
pi
could
advantag
mechan
lead
attenu
airway
inflamm
zhu
et
al
howev
studi
need
clarifi
effect
ergoferon
cytokin
cellular
respons
rv
infect
asthma
interestingli
level
bal
cell
count
cytokin
fig
proinflammatori
cytokin
chemokin
level
bronchoalveolar
lavag
supernat
transgen
balbc
mice
anim
infect
tcid
given
test
sampl
diluent
twice
daili
within
day
day
viral
inocul
mg
refer
product
per
mous
administ
intranas
h
prior
infect
b
c
chemokin
level
p
differ
ergoferon
refer
group
p
signific
differ
ergoferon
diluent
result
determin
elisa
h
h
h
pi
n
ergoferon
refer
group
n
mice
per
diluent
group
data
assess
kruskalw
test
posthoc
nemenyi
analysi
present
mean
sem
especi
level
neutrophil
huicam
group
higher
compar
ergoferontr
mice
equal
diluent
group
probabl
huicam
reduc
rvinduc
allerg
airway
inflamm
h
pi
instanc
traub
colleagu
show
signific
reduct
bal
cell
profil
huicam
dose
mgmice
h
pi
measur
earlier
timepoint
traub
et
al
take
togeth
observ
result
studi
demonstr
antivir
effect
ac
vitro
benefici
respons
ergoferon
vivo
ac
treatment
show
evid
induct
express
togeth
reduct
viral
replic
ergoferon
turn
present
increas
ifn
product
reduct
cell
cytokin
profil
vivo
sum
propos
drug
could
therefor
candid
develop
novel
treatment
ill
includ
induc
rhinovirus
